Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Analyst Ratings
This is a summary of current ratings and recommmendations for Jupiter Neurosciences and Silo Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jupiter Neurosciences | 1 | 0 | 0 | 0 | 1.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Jupiter Neurosciences and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jupiter Neurosciences | N/A | N/A | -246.66% |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
Institutional and Insider Ownership
5.6% of Silo Pharma shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by insiders. Comparatively, 3.6% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Jupiter Neurosciences has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Valuation and Earnings
This table compares Jupiter Neurosciences and Silo Pharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jupiter Neurosciences | $64,693.00 | 31.05 | -$8.65 million | ($19.12) | -0.12 |
| Silo Pharma | $54,077.00 | 39.06 | -$4.23 million | ($4.36) | -0.31 |
Silo Pharma has lower revenue, but higher earnings than Jupiter Neurosciences. Silo Pharma is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Jupiter Neurosciences beats Silo Pharma on 6 of the 11 factors compared between the two stocks.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
